Endothelial cell activation by immunoglobulins from patients with immune thrombocytopenic purpura or with antiphospholipid syndrome

Haematologica

Volumn 93, Issue 4, 2008, Pages 635-636

  Dunoyer Geindre, Sylvie ^a   Boehlen, Françoise ^a   Favier, Remi ^b   Wahl, Denis ^c   Musial, Jacek ^d   Korte, Wolfgang ^e   Satta, Nathalie ^a   Kruithof, Egbert ^a   De Moerloose, Philippe ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c Department of Medicine ^*  (France)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Endothelial cell activation; Immune thrombocytopenic purpura

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN G; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AFFINITY CHROMATOGRAPHY; AGED; ANTIPHOSPHOLIPID SYNDROME; BLOOD SAMPLING; CELL ACTIVATION; CLINICAL FEATURE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LETTER; MAJOR CLINICAL STUDY; MALE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 42149093162     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12358     Document Type: Letter

References (12)

1. Kravitz M, Schoenfeld Y. Thrombocytopenic conditions - Autoimmunity and hypercoagulability: commonalities and differences in ITP, TTP, HIT, and APS. Am J Hematol 2005;60:232-42.
2. Bidot CJ, Jy W, Horstman LL, Ahn ER, Yaniz M, Ahn YS. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol 2006;81:391-6.
3. Diz-Küçukkaya R, Hacihanefioglu A, Yenerel M, Turgut M, Keskin H, Nalçaci M, lnanç M. Antiphospholipid anti-bodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001;98:1760-4.
4. de Groot PG, Derksen RH. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 2005;3:1854-60.
5. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001;88:245-50.
6. Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B, Reber G, Kruithof EKO. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-b(2)-glycoprotein 1 antibodies. Thromb Haemost 2002;88:851-7.
7. Meroni PL, Raschi E, Testoni C, Borghi MO. Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004;112:169-74.
8. Dunoyer-Geindre S, Kruithof EKO, Boehlen F, Satta-Poschung N, Reber G, de Moerloose P. Aspirin inhibits endothelial cell activation induced by antiphospholipid antibodies. J Thromb Haemost 2004;2:1176-81.
9. Jy W, Tiede M, Bidot CJ, Horstman LL, Jimenez JJ, Chirinos J, et al. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res 2007;121:319-25.
10. Harris EN, Gharavi AE, Hegde U, Derue G, Morgan SH, Englert H, et al. Anticardiolipin antibodies in autoimmune thrombocytopenic purpura. Br J Haematol 1985;59:231-4.
11. Nojima J, Sueshisa E, Kuratsune H, Machii T, Koike T, Kitani T, et al. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG anti-bodies in patients with systemic lupus erythematosus-possible association with thrombotic and thrombocytopenic complications. Thromb Haemost 1999;81:436-41.
12. Atsumi T, Surukawa S, Amengual O, Koike T. Anti-phospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 2005; 14:499-504.